Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma | Business Wire
A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer | British Journal of Cancer
Efficacy endpoints in Oncology
ORR (Objective Response Rate) and related statistics – Part 1
PDF] Objective response rate assessment in oncology: Current situation and future expectations | Semantic Scholar
Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer - ScienceDirect
ORR (Objective Response Rate) and related statistics – Part 1
ORR (Objective Response Rate) and related statistics – Part 1
Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer - ScienceDirect
Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Phase 2 Oncology Trials - Dello Russo - 2021 - The Journal of Clinical Pharmacology - Wiley Online Library
Best tumor response and overall response rate (ORR) by disease site (n... | Download Table
Comparison of objective response rate (ORR) according to the presence... | Download Scientific Diagram
Analysis of objective response rate (ORR). a ORR of 13 RCTs. Subgroup... | Download Scientific Diagram
A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer | British Journal of Cancer
Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer - ScienceDirect
The analysis of objective response rate (ORR) between 2 groups based on... | Download Scientific Diagram
PDF] Objective response rate assessment in oncology: Current situation and future expectations | Semantic Scholar
Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer - ScienceDirect
Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Phase 2 Oncology Trials - Dello Russo - 2021 - The Journal of Clinical Pharmacology - Wiley Online Library